IDPC describes de public health impact of punitive law enforcement on women who use drugs, offering recommendations for an evidence-informed and gender-sensitive response to drug use and HIV.
Canêdo et al. challenge the notion that the harm reduction needs of young people who use drugs are being met and provide ten calls to action to improve support and access for young people.
Drug Policy Voices emphasises the importance of integrating the views and experiences of people who use drugs into future research and activism, also highlighting how values and ideology are influenced by a broader set of factors than personal drug use
Iga Jeziorska notes progress in the range and quality of services whilst underscoring dramatic disparities in access along regional, urban/rural and other divides.
C-EHRN provides an overview of how harm reduction policies and programmes are implemented in the region, with valuable insights on civil society engagement.
The Pompidou Group analyses the impact of parental drug use on children, highlighting how criminalising and stigmatising policies create further harm to children, with suggestions to improve drug policy to address the needs of both children and parents who use drugs.
The Council of Europe offers a self-assessment tool to encourage states to better understand the situation on the ground and consider reforms as needed.
WHO Director-General offers an overview of recent developments, including in relation to the impact of the COVID-19 pandemic and access to controlled medicines, and calls for a public health approach.
Rivera-Aguirre et al. identified no changes in the prevalence of risky and frequent cannabis use among secondary school students following the legal regulation of cannabis
Birgin et al. document how state-driven stigma, criminalisation, and abuse create gendered barriers in access to services and drive women imprisonment, prompting mobilisation in resistance.
IDPC and the GDPO analyse the limitations of the data and methodologies in the report, and explore the implications of these shortcomings for drug policy in Africa.